Author:
Seto T,Yoh K,Asoh H,Yamamoto H,Semba H,Ichinose Y
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1535–1540
2. Bunn Jr PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Research 5: 1087–1100
3. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Giuliodori L, Pessi MA, Fusco V, Luporini G, Cellerino R, Catalano G (1999) A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 80: 1595–1598
4. Cortes-Funes H, Martin C, Abratt R, Lund B (1997) Safety profile of gemcitabine, a novel anticancer agent in non-small cell lung cancer. Anti-cancer Drugs 8: 582–587
5. Feliu J, Lopez Alvarez MP, Jaraiz MA, Constenla M, Vicent JM, Belon J, Lopez Gomez L, de Castro J, Dorta J, Gonzalez Baron M (2000) Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. Cancer 89: 1706–1713
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献